Sub Saharan Africa

Cipla has licensed Sino Biopharm's HER2 biparatopic ADC TQB2102 for India, South Africa and five other emerging markets. The deal caps at USD 123 million plus double-digit royalties, with access to HER2-low breast cancer as the core case. #SyenzaNews #Oncology #MarketAccess #DrugDevelopment

South Africa is preparing to register and introduce a new tuberculosis vaccine if late-stage Phase 3 trials succeed. Cabinet confirmed the plans this week and welcomed a Serum Institute of India agreement to manufacture TB vaccines for global distribution. #SyenzaNews #globalhealth #clinicaltrials #MarketAccess

South Africa’s health department pushes back on claims that state tenders are hollowing out pharmaceutical manufacturing, arguing the sector’s real pressures are regulatory rather than the result of procurement decisions.

🔑 How is South Africa’s SEP adjustment safeguarding pharma supply security? The latest Single Exit Price adjustment seeks to balance affordability with manufacturer sustainability, helping to stabilise medicine availability amid economic pressures. Read the full analysis to see what it means for pricing, supply chains and market access. #SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

South Africa's drugmakers and the health department are at odds over lowest-price tenders. Pharmisa says cheaper imports have cost more than 2,500 jobs and eroded local manufacturing capacity.

💰 Is pembrolizumab delivering high value for HNSCC in Switzerland? A new analysis confirms the immunotherapy offers strong cost-effectiveness, supporting smarter resource allocation and improved patient outcomes in oncology. Explore the full economic evaluation and its implications for market access. #SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

🚀 How is the India-SACU trade agreement unlocking new pharma growth? This landmark deal is expanding market access, cutting tariffs, and accelerating exports for Indian pharmaceutical companies across Southern Africa. Discover the strategic opportunities it creates for the sector. #SyenzaNews #pharmaceuticals #globalhealth #innovation #MarketAccess

Can local procurement policies turn the tide for South Africa’s pharmaceutical jobs? A strategic shift toward prioritizing local pharma manufacturing could safeguard thousands of positions while strengthening supply chain resilience and economic growth. This approach balances cost considerations with long-term industrial development in the sector. Explore the full analysis. #SyenzaNews #pharmaceuticals #MarketAccess #healthcarepolicy

How is South Africa advancing local production of cutting-edge HIV treatments? The country has shortlisted manufacturers for Lenacapavir, paving the way for greater domestic capacity, improved access, and stronger pharmaceutical supply chains across the region. Explore how this step supports broader drug development goals. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

Is Africa's HIV future at a crossroads? The Africa HIV Control Working Group's 2026 webinar spotlighted UNAIDS, UNICEF & health leaders on domestic financing, sovereignty, integrated systems & community leadership to build resilient HIV control. Read more & join the push for bold action. #HIVControl #AfricaHealth #BoldLeadership #UNAIDS #GlobalHealth

🧪 Could a blood-based test be the breakthrough Africa needs to turn the tide on TB? A new diagnostic approach is significantly improving case detection rates, enabling earlier intervention in high-burden regions. Discover how this innovation is reshaping tuberculosis control strategies. #SyenzaNews #globalhealth #biotechnology #innovation

🌍 How is Africa strengthening its vaccine independence? Recent expansions are significantly boosting Biovac’s manufacturing capacity, enabling greater local production and reducing reliance on imports. This marks a key step toward sustainable vaccine supply across the continent. Read the full story. #SyenzaNews #biotechnology #globalhealth #innovation